Related Experiment Videos
[Serotonin syndrome. Which treatment and when?]
E Jaunay1, V Gaillac, J D Guelfi
1C.H. Sainte-Anne, Service du Pr. Guelfi, 100 rue de la santé, F75014 Paris. e.jaunay@caramail.com
Presse Medicale (Paris, France : 1983)
|January 5, 2002
Summary
Serotonin syndrome, a potentially fatal toxic reaction, is increasingly prevalent due to excessive central serotonin receptor stimulation. Early diagnosis and drug withdrawal are key, with cyproheptadine and chlorpromazine offering specific treatment options.
Area of Science:
- Pharmacology
- Toxicology
- Neuroscience
Context:
- Serotonin syndrome prevalence is rising, posing a significant health risk.
- The condition is primarily linked to excessive stimulation of central serotonin 5HT1a receptors.
- Monoamine oxidase inhibitors are frequently implicated as causative agents.
Purpose:
- To review the increasing prevalence and pathophysiology of serotonin syndrome.
- To discuss revised diagnostic criteria and differential diagnoses, including neuroleptic malignant syndrome.
- To outline current and proposed therapeutic strategies for managing serotonin syndrome.
Summary:
- The physiopathology of serotonin syndrome involves overstimulation of central 5HT1a receptors, with monoamine oxidase inhibitors being common culprits.
- Revised diagnostic factors expand on Sternbach's classical triad (neuropsychiatric, neuromuscular, neurovegetative symptoms).
- Early detection and drug withdrawal are crucial; symptomatic care is foundational, with cyproheptadine and chlorpromazine as targeted treatments for severe cases.
Impact:
- Highlights the need for increased awareness and prompt recognition of serotonin syndrome.
- Provides guidance on updated diagnostic approaches and differential diagnosis.
- Offers evidence-based recommendations for specific pharmacological interventions in severe or persistent cases.